Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2020 11:15 ET | Source: Vaccinex, Inc.

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
October 29, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
October 26, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable

ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
September 22, 2020 07:30 ET | Source: Vaccinex, Inc.

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
September 17, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...
August 27, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer

ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
August 14, 2020 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised...
July 07, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
June 09, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
May 14, 2020 08:45 ET | Source: Vaccinex, Inc.

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 ...